Octreotide in Severe Polycystic Liver Disease

NCT00426153 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant
Polycystic Liver Disease
Hepatomegaly
Liver Diseases
Kidney, Polycystic
Abdominal Pain

Interventions

DRUG: Octreotide
DRUG: Placebo

Sponsor

Mayo Clinic

Collaborators

[object Object]
[object Object]